KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Long-Term Debt Repayments (2016 - 2025)

Gilead Sciences (GILD) has disclosed Long-Term Debt Repayments for 17 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments rose 14.29% year-over-year to $8.0 million, compared with a TTM value of $1.8 billion through Dec 2025, down 9.24%, and an annual FY2025 reading of $1.8 billion, down 9.24% over the prior year.
  • Long-Term Debt Repayments was $8.0 million for Q4 2025 at Gilead Sciences, down from $9.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.5 billion in Q3 2021 and bottomed at $7.0 million in Q4 2024.
  • Average Long-Term Debt Repayments over 5 years is $942.9 million, with a median of $1.0 billion recorded in 2021.
  • The sharpest move saw Long-Term Debt Repayments skyrocketed 150.0% in 2021, then plummeted 99.51% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $1.0 billion in 2021, then changed by 0.0% to $1.0 billion in 2022, then surged by 125.0% to $2.2 billion in 2023, then crashed by 99.69% to $7.0 million in 2024, then grew by 14.29% to $8.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for GILD at $8.0 million in Q4 2025, $9.0 million in Q3 2025, and $9.0 million in Q2 2025.